MacroGenics, Inc. · NASDAQ:MGNX

MacroGenics — Corporate Update (November 2026)

28 slides from MacroGenics's corporate update, Nov 13, 2026

  1. Slide 1: Corporate Update November 12, 2026

    Corporate Update November 12, 2026

  2. Slide 2: Legal Notices

    2 November 12, 2026 Legal Notices The information in this slide deck is current as of November 12, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any

  3. Slide 3: Resourced to Deliver on Plan

    3 November 12, 2026 (1) TZIELD® was sold to Provention Bio (Sanofi) and is marketed by Sanofi; ZYNYZ® was licensed to, and is marketed by, Incyte. MARGENZA® was sold to, and is marketed by, TerSera Therapeutics LLC. (2) Includes $119.6M proceeds, before fees and expenses, from sale of manufacturing

  4. Slide 4: Innovative Product Pipeline with Significant Rights Retained

    4 November 12, 2026 Program Target / Modality Lead Indication(s) Preclinical Phase 1 Dose Finding Phase 1/2 PoC Phase 2/3 Pivotal Partner Antibody Drug Conjugates MGC026 B7-H3 / TOP1i SCCHN, Endometrial, Melanoma, Sarcoma — MGC028 ADAM9 / TOP1i Solid Tumors — MGC030 Undisclosed / TOP1i Solid Tumors

  5. Slide 5: MGC026: Well-Positioned in Emerging Category of B7-H3 ADCs

    5 November 12, 2026 Significant Interest in B7-H3 ADCs • Significant market interest in B7-H3-targeting ADCs ü Multiple major pharma partnerships announced ü Broad clinical validation established in >15 different tumors •Opportunity to build favorable market position in competitive space across mult

  6. Slide 6: MGC026: Designed as Potential Best-in-Class B7-H3 ADC

    6 November 12, 2026 MGC026: Designed as Potential Best-in-Class B7-H3 ADC Abbreviations: DAR: drug to antibody ratio. (1) Comparisons between MGC026 and competing B7-H3 ADCs based on non-clinical data. No head-to-head studies have been conducted evaluating MGC026 against competing molecules, caution

  7. Slide 7: MGC026 Differentiated From Competing B7-H3 ADCs

    7 November 12, 2026 MGC026 Differentiated From Competing B7-H3 ADCs(1) Furthest Advanced B7-H3 ADCs: MGC026 Ifinatamab Deruxtecan (I-DXd, DS-7300) Risvutatug Rezetecan (HS-20093/GSK5764227) YL201 DB-1311/ BNT345 Company/ Partner Linker (Site-specific?) GlycoConnect- HydraSpace- VA-PABC GGFG Tetrapep

  8. Slide 8: MGC026 Phase 1 FIH Study: Dose Escalation Followed by Expansion

    8 November 12, 2026 Key Inclusion Criteria § Locally advanced/metastatic solid tumors § Measurable disease by RECIST v1.11 § ECOG 0-1 Key Exclusion Criteria § Prior treatment with: - B7-H3 targeted agent - TOP1i ADC § Prior stem cell or solid organ transplant Endpoints § Scan Frequency: Q9W through

  9. Slide 9: Dose Escalation: Encouraging Antitumor Activity Observed

    9 November 12, 2026 Lorigerlimab MGD024MGC028 MGC030MGC026 -100 -80 -60 -40 -20 0 20 40 60 80 100 Dose Escalation: Encouraging Antitumor Activity Observed (6 – 9 mg/kg; N = 32(1)) Abbreviations: DCR: disease control rate; PR: partial response; SD: stable disease. (1) 26 response evaluable participan

  10. Slide 10: SCCHN Expansion: Primarily Heavily Pre-treated Patients

    10 November 12, 2026 SCCHN Expansion: Primarily Heavily Pre-treated Patients with 3+ Prior Lines of Therapy Characteristic Total N = 27; n (%) Age, median (min-max) 61 (35.0, 79.0) Sex, n (%) Female Male 6 (22.2) 21 (77.8) Race, n (%) White Asian Black or African American Other/Unknown 19 (70.4) 3 (

  11. Slide 11: Case Study: Confirmed PR in 5th-Line Metastatic Oropharyngeal Cancer Patient

    11 November 12, 2026 Case Study: Confirmed PR in 5th-Line Metastatic Oropharyngeal Cancer Patient 58.1% target lesion reduction Target Burden Summary (5 lesions) Baseline size (SLD): 215 mm 9 Weeks size (SLD): 90 mm % Change from baseline: -58.1% Baseline 9 Weeks Abbreviations: CR: complete response

  12. Slide 12: SCCHN Expansion Cohort: 27.3% Best Overall Response Rate

    12 November 12, 2026 SCCHN Expansion Cohort: 27.3% Best Overall Response Rate (1) Best ORR as defined by confirmed and/or unconfirmed responses; (2) CPS score based on analysis of tumor sample collected while on treatment; all other CPS scores are based on samples collected at screening; HPV status

  13. Slide 13: SCCHN Expansion: Duration of Treatment and Tumor Response

    13 November 12, 2026 SCCHN Expansion (7.5 mg/kg Q3W): Duration of Treatment and Tumor Response Data cutoff: September 1, 2026; data are not final and subject to change. Presented at ESMO 2026. Lorigerlimab MGD024MGC028 MGC030MGC026

  14. Slide 14: SCCHN Expansion: Manageable Safety Profile

    14 November 12, 2026 SCCHN Expansion: Manageable Safety Profile Safety Parameters 7.5 mg/kg Q3W (N=27) N(%) Any TRAE 23 (85.2) Treatment Related GR3+ 13 (48.1) TRAE Resulting in Drug Interruption 7 (25.9) TRAE Resulting in Dose Reduction 9 (33.3) TRAE Resulting in Treatment Discontinuation 0 (0.0) (

  15. Slide 15: MGC026 Well Positioned in SCCHN Across Emerging ADCs

    15 November 12, 2026 We Believe MGC026 is Well Positioned in SCCHN Across Emerging ADCs (1) MacroGenics; data cutoff: September 1, 2026; data are not final and subject to change; (2) Johnson, et al., Lancet Oncol., 2026; (3) Zhang, et al., ASCO'26; dose expansion data; (4) Liu, et al., ASCO'26; (5)

  16. Slide 16: Enhanced MGC026 Antitumor Activity in Combination with CPI

    16 November 12, 2026 0 10 20 30 40 50 60 0 500 1000 1500 2000 2500 3000 3500 Vehicle MGC026, 6 mg/kg Study Day Tu m or V ol um e (m m 3 ) anti-PD-1 10 mg/kg MGC026 + anti-PD-1 MGC026 anti-PD1 Enhanced MGC026 Antitumor Activity in Combination with CPI in Preclinical Models MGC026 profile supports fut

  17. Slide 17: MGC026 Summary: Promising Development Path in SCCHN

    17 November 12, 2026 MGC026 Summary: Promising Development Path in SCCHN 0% TRAEs leading to discontinuation (SCCHN) 27% Best Overall Response in late line SCCHN 31% Best Overall Response in HPV+ patients 64% Disease control rate 0 Cases ILD/pneumonitis or ocular toxicity to date Differentiated B7-H

  18. Slide 18: MGC028: Potential First-in-Class ADAM9 ADC

    18 November 12, 2026 MGC028: Potential First-in-Class ADAM9 ADC MGC028 is investigational and has not yet been approved for marketing by any regulatory authority (1) Based on October 10, 2026 data cutoff; data are not final and subject to change. • ADAM9 (A Disintegrin And Metalloprotease 9) ‒ Plays

  19. Slide 19: MGC028: Preclinical Profile Supports Broad Development Opportunity

    19 November 12, 2026 91% 80% 72% 67% 55% 37% 24% 6% 15% 14% 5% 17% 9% 3% 20% 13% 19% 40% 46% 67% 0% 20% 40% 60% 80% 100% CRC (n=123) NSCLC - Adeno (n=15) Pancreatic (n=60) Cholangio (n=36) Gastric CA (n=20) TNBC (N=122) NSCLC - SCC (N=21) % o f S am pl e w ith In di ca te d H -s co re 100+ 30 - 99 0

  20. Slide 20: MGC030: Potential First-in-Class ADC

    20 November 12, 2026 MGC030: Potential First-in-Class ADC MGC030 is investigational and has not yet been approved for marketing by any regulatory authority • First patient dosed in Phase 1 study • Eligible indications: urothelial, colorectal, gastric or GEJ, esophageal, and pancreatic cancers • Enco

  21. Slide 21: Lorigerlimab (PD-1 × CTLA-4): DART Molecule with Two Validated Checkpoint Targets

    21 November 12, 2026 Lorigerlimab (PD-1 × CTLA-4): DART Molecule with Two Validated Checkpoint Targets (1) Data cutoff: September 1, 2026; data are not final and subject to change. Abbreviations: CCGC: Clear Cell Gynecologic Cancer. Dual Checkpoint Blockade • Maintains PD-1 inhibition of PD-1 mAbs o

  22. Slide 22: Lorigerlimab Demonstrated Superior in Vivo Checkpoint Blockade vs. Volrustomig

    22 November 12, 2026 Lorigerlimab Demonstrated Superior in Vivo Checkpoint Blockade vs. Volrustomig 0.0001 0.01 1 100 0 100 200 300 400 Jurkat CTLA-4 Concentration(ug/mL) B7 -1 b in di ng , M FI 0.0001 0.01 1 100 0 50 100 150 200 250 Jurkat PD-1/CTLA-4 Concentration(ug/mL) B7 -1 b in di ng , M FI 0.

  23. Slide 23: Lorigerlimab: PROC and CCGC Phase 2 Study Design Summary

    23 November 12, 2026 Key Inclusion criteria • ≥1 Prior line • PARP allowed (not req’d) Key Exclusion criteria • Primary platinum- refractory disease Lorigerlimab: PROC and CCGC Phase 2 Study Design Summary Abbreviations: CCGC: clear cell gynecologic cancer Plan to enroll 20 add’l CCGC patients @3 mg

  24. Slide 24: Lorigerlimab: Encouraging Interim Phase LINNET Results (CCGC Cohort)

    24 November 12, 2026 Lorigerlimab: Encouraging Interim Phase 2 LINNET Results (CCGC Cohort) Lorigerlimab MGD024MGC028 MGC030MGC026 (a) MSS/MSI-L (b) Low probability of MSI-H. Data cutoff: September 1, 2026; data are not final and subject to change. Presented at ESMO 2026.

  25. Slide 25: Clear Cell Gynecologic Cancer Patients Need Better Treatment Options

    25 November 12, 2026 (1) Tan, et al., ASCO’14 Poster - across all lines of treatment, ORR was 9% and mPFS was 11-weeks. (2) Includes ovarian, endometrial, and cervical cancer. (3) G7 includes US, ES, IT, UK, FR, DE, and JP. Source: GlobalData; NCCN Clear Cell Gynecologic Cancer Patients Need Better

  26. Slide 26: MGD024: CD123 × CD3 DART Molecule

    26 November 12, 2026 • Anti-leukemic activity in vitro and in murine tumor models • Good tolerability in cynos with reduced cytokine release • PK profile consistent with dosing patient on weekly basis or longer interval • Combinable with standard-of-care agents CD3 CD123 Fc-silenced IgG1 MGD024: CD1

  27. Slide 27: Well Resourced to Execute on Strategic Priorities

    27 November 12, 2026 Well Resourced to Execute on Strategic Priorities (1) Does not include $150.9M of Other Income (“Gain on royalty monetization arrangement”). 9 Mos. Ended Sep. 30, $ in Millions 2022 2023 2024 2025 2025 2026 Total Revenues $152 $59(1) $150 $150 $67 $58 R&D Expense 207 167 177 147

  28. Slide 28: Thank You!

    28 November 12, 2026 Thank You! Investor Relations Inquiries Jim Karrels – SVP, Chief Financial Officer karrelsj@macrogenics.com Argot Partners macrogenics@argotpartners.com www.macrogenics.com Link to our latest presentations: http://ir.macrogenics.com/events.cfm Business Development Inquiries Hari

MacroGenics — Corporate Update (November 2026) on 6ix